Navigation Links
Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2007 Financial Results

- Annual Xyrem(R) Net Sales Increase 34 Percent

- Investor Day Scheduled for March 13, 2008

PALO ALTO, Calif., Feb. 13 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) today announced financial results for the fourth quarter and full year ended December 31, 2007.

Total revenues for the quarter ended December 31, 2007 were $15.5 million, compared to $12.4 million for the quarter ended December 31, 2006. Total revenues for the year ended December 31, 2007 increased 46 percent to $65.3 million, compared to $44.9 million for the year ended December 31, 2006. Xyrem(R) (sodium oxybate oral solution) net sales for the quarter ended December 31, 2007 increased 38 percent to $11.1 million, compared with $8.1 million for the last quarter of 2006. Xyrem net sales for the year ended December 31, 2007 increased 34 percent to $39.0 million, compared with $29.0 million for the year ended December 31, 2006.

"We are very pleased with the momentum we achieved in 2007. Our focus in 2008 will be on execution, including the planned commercial launch of LUVOX(R) CR in the first quarter of 2008 after anticipated FDA approval," said Samuel R. Saks, M.D., Chief Executive Officer. "Our portfolio of development-stage product candidates is making steady progress, and we believe that our development efforts will lead to important new products for patients and caregivers."

Jazz Pharmaceuticals' net loss for the fourth quarter of 2007 was $60.0 million, compared to a net loss of $20.5 million for the fourth quarter of 2006. For the year ended December 31, 2007, the company's net loss was $138.8 million, compared to a net loss of $59.4 million for the year ended December 31, 2006. Net loss for the year ended December 31, 2007 included:

-- a $20.2 million non-cash reduction in the carrying value of the

intangible asset related to Antizol(R) (fomepizole) as a result of the

approval and introduction of a generic competitor;

-- a $17.5 million charge related to a previously announced settlement

with the United States government, of which $1.0 million was paid in


-- $9.5 million of contract revenue resulting from milestone payments

under Jazz Pharmaceuticals' agreement with UCB; and

-- a $5.1 million gain on the divestiture of Cystadane(R) (betaine

anhydrous for oral solution).

Net loss for the year ended December 31, 2006 included a $31.6 million non-cash gain on extinguishment of a development financing obligation in connection with a terminated development program.

Research and development expenses for the quarter ended December 31, 2007 were $20.5 million, compared to $13.0 million for the quarter ended December 31, 2006. For the year ended December 31, 2007, research and development expenses were $69.8 million, compared to $55.0 million for the year ended December 31, 2006. The increase in research and development expenses in 2007 reflects expanded Phase III clinical trial activities for JZP-6, LUVOX CR scale-up and manufacturing costs and increased headcount.

Selling, general and administrative expenses for the quarter ended December 31, 2007 were $28.0 million, compared to $12.5 million for the quarter ended December 31, 2006. For the year ended December 31, 2007, selling, general and administrative expenses were $78.5 million, compared to $51.4 million for the year ended December 31, 2006. The increase in both periods was primarily due to spending in preparation for the anticipated launch of Once-A-Day LUVOX CR (fluvoxamine maleate) Extended-Release Capsules, increased headcount and higher expenses to support the company's sales force, offset in part by lower legal fees.

Jazz Pharmaceuticals' unrestricted cash, cash equivalents and marketable securities balance as of December 31, 2007 was $102.9 million. Net operating cash used during the year ended December 31, 2007 was $81.1 million.

Recent Highlights

-- On January 31, 2008, Jazz Pharmaceuticals announced that the U.S. Food

and Drug Administration (FDA) had accepted for review the submission of

the response by Solvay Pharmaceuticals, Inc. to the FDA approvable

letter for LUVOX CR. The FDA notified Solvay Pharmaceuticals that it

considered this a complete, class 1 response and the PDUFA action date

is February 29, 2008. In an approvable letter received on

December 21, 2007, the FDA had requested additional information

concerning a chemistry, manufacturing and control (CMC) issue. The

approvable letter did not raise any questions related to safety or

efficacy of LUVOX CR and included the FDA's proposed labeling. Jazz

Pharmaceuticals and Solvay Pharmaceuticals believe that the response

submitted to the FDA on December 28, 2007 fully addressed that CMC


-- Jazz Pharmaceuticals has completed the expansion of its sales force,

and now has a total of approximately 200 field sales personnel,

including sales management and sales representatives. These

individuals are currently in their assigned sales territories promoting


-- In early January 2008, Jazz Pharmaceuticals announced that it had

received orphan drug designation from the FDA for its JZP-8 product

candidate for the treatment of recurrent acute repetitive seizures.

JZP-8 is a novel drug delivery formulation incorporating clonazepam, a

widely prescribed benzodiazepine. The product candidate is designed to

be a fast-acting intranasal spray for the treatment of recurrent acute

repetitive seizures in patients with epilepsy. In December 2007, Jazz

Pharmaceuticals dosed the first patient in a Phase II clinical trial of


-- A single dose pharmacokinetic study of a controlled-release formulation

of JZP-4, a product candidate for the treatment of partial epilepsy and

bipolar disorder, was completed in the fourth quarter of 2007, and

Phase II clinical trial activities are underway.

Jazz Pharmaceuticals will be hosting an Investor Day on March 13, 2008 beginning at 10:00 a.m. Eastern Time/7:00 a.m. Pacific Time. The event will include presentations by Jazz Pharmaceuticals executives and by Dr. Mark H. Pollack, a noted psychiatrist at Massachusetts General Hospital and Professor at Harvard Medical School, who will speak about obsessive compulsive disorder and social anxiety disorder. The event will be available by live audio webcast, and the accompanying presentation materials will also be available on the investor relations section of Jazz Pharmaceuticals' web site at

Jazz Pharmaceuticals will host an investor conference call and live audio webcast to discuss its financial results and provide a business update on its commercial and development activities on February 13, 2008 commencing at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. The live webcast may be accessed on Jazz Pharmaceuticals' website at Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary. An archived version of the webcast will be available through February 27, 2008. Investors may participate in the conference call by dialing 1-800-299-0148 in the U.S., or 1-617-801-9711 outside the U.S., and entering passcode 72272011. A replay of this call will be available until February 27, 2008 by phone at 1-888-286-8010 (U.S.), or 1-617-801-6888 (international), using the passcode 23908777.

About Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. For further information see

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements, including, but not limited to, statements related to the anticipated regulatory approval and planned commercial launch of LUVOX CR and the continued development of Jazz Pharmaceuticals' product candidates. These forward-looking statements are based on the company's current expectations and inherently involve significant risks and uncertainties. Jazz Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, the risk that the FDA may not approve LUVOX CR for marketing in the United States; risks related to the launch of LUVOX CR; risks related to the development of Jazz Pharmaceuticals' product candidates, including the risk that study or clinical trial results may require Jazz Pharmaceuticals to discontinue the development of one or more product candidates; and risks related to the uncertain and time-consuming regulatory approval process. These and other risk factors are discussed under "Risk Factors" in the Quarterly Report on Form 10-Q for the quarter ended September 30, 2007 filed by Jazz Pharmaceuticals with the Securities and Exchange Commission on November 9, 2007. Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.



(In thousands, except per share amounts)


Three Months Ended Year Ended

December 31, December 31,

2007 2006 2007 2006


Product sales, net $14,860 $11,890 $53,536 $43,299

Royalties, net 332 258 1,156 594

Contract revenue 285 301 10,611 963

Total revenues 15,477 12,449 65,303 44,856

Operating expenses:

Cost of product sales

(excluding amortization of

acquired developed

technology) 3,283 1,601 8,903 6,968

Research and development 20,540 13,036 69,792 54,956

Selling, general and

administrative 27,958 12,543 78,540 51,384

Intangible asset

amortization 2,280 2,400 9,217 9,600

Intangible asset impairment 20,160 - 20,160 -

Provision for government

settlement - - 17,469 -

Total operating expenses 74,221 29,580 204,081 122,908

Loss from operations (58,744) (17,131) (138,778) (78,052)

Interest income 1,582 619 5,942 2,307

Interest expense (3,554) (3,311) (13,647) (14,129)

Other income (expense) (19) (712) 1,797 (1,109)

Gain on extinguishment of

development financing

obligation - - - 31,592

Gain on sale of products 715 - 5,860 -

Net loss (60,020) (20,535) (138,826) (59,391)

Beneficial conversion

feature - (18,419) - (21,920)

Loss attributable to common

stockholders $(60,020) $(38,954) $(138,826) $(81,311)

Loss per share attributable

to common stockholders,

basic and diluted $(2.53) $(2,043.15) $(10.04) $(6,254.69)

Weighted-average common

shares used in computing

loss per share attributable

to common stockholders,

basic and diluted 23,694 19 13,829 13



(In thousands)


Three Months Ended Year Ended

December 31, December 31,

2007 2006 2007 2006

Xyrem $11,120 $8,082 $39,018 $29,049

Antizol 3,740 3,472 14,153 12,813

Cystadane (1) - 336 365 1,437

Total $14,860 $11,890 $53,536 $43,299

(1) Jazz Pharmaceuticals, Inc. sold its rights to Cystadane to an

unrelated third party in March 2007.



(In thousands)


December 31,

2007 2006


Current assets:

Cash and cash equivalents $102,945 $78,948

Restricted cash 1,939 275

Accounts receivable, net 5,389 5,380

Inventories 2,213 3,026

Prepaid expenses 3,224 3,447

Other current assets 381 487

Total current assets 116,091 91,563

Property and equipment, net 3,941 2,107

Intangible assets, net 36,040 69,140

Goodwill 38,213 38,213

Long-term restricted cash and investments 12,000 12,000

Other long-term assets 1,269 1,548

Total assets $207,554 $214,571



Current liabilities:

Line of credit $3,459 $2,191

Accounts payable 2,856 5,443

Accrued liabilities 29,047 12,943

Deferred revenue 1,494 1,422

Preferred stock warrant liability - 8,521

Total current liabilities 36,856 30,520

Deferred rent and other non-current

liabilities - 534

Non-current portion of deferred revenue 12,468 13,495

Liability under government settlement 14,881 -

Senior secured notes 75,116 74,283

Convertible preferred stock - 263,852

Common stock subject to repurchase 13,241 8,183

Stockholders' equity (deficit):

Common stock 2 -

Additional paid-in capital 371,440 1,335

Accumulated other comprehensive income 19 12

Accumulated deficit (316,469) (177,643)

Total stockholders' equity (deficit) 54,992 (176,296)

Total liabilities, convertible

preferred stock and stockholders'

equity (deficit) $207,554 $214,571

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
2. Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
3. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
4. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
5. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
6. NPS Pharmaceuticals, Inc. Announces an Increase in Tender Offer Price for Its 3.0% Convertible Notes Due 2008 and Extends Expiration Date Until October 17, 2007
7. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
8. Jazz Pharmaceuticals, Inc. Announces Changes to its Board of Directors
9. Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
11. Jazz Pharmaceuticals, Inc. to Announce Third Quarter 2007 Financial Results on November 6, 2007
Post Your Comments:
(Date:10/10/2017)... CA (PRWEB) , ... October ... ... a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today ... of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration ...
(Date:10/10/2017)... Parks Associates announced today that Tom Kerber , Director ... , October 11 in Scottsdale, Arizona . Kerber will ... safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and the introduction of ...
(Date:10/10/2017)... ... 10, 2017 , ... The Pittcon Program Committee is pleased ... scientists who have made outstanding contributions to analytical chemistry and applied spectroscopy. Each ... leading conference and exposition for laboratory science, which will be held February 26-March ...
(Date:10/9/2017)... Charlotte, N.C. (PRWEB) , ... October 09, 2017 , ... ... Purple announced Dr. Christopher Stubbs, a professor in Harvard University’s Departments of Physics and ... Dr. Stubbs was a member of the winning team for the 2015 Breakthrough Prize ...
Breaking Biology Technology:
(Date:8/23/2017)... Aug. 23, 2017  The general public,s help is being enlisted in ... that live in and on the human body –and are believed to ... The Microbiome Immunity Project ... microbiome, starting with the gut. The project's goal is to help advance ... IBM ...
(Date:7/20/2017)... Delta (NYSE: DAL ) customers now can use ... Reagan Washington National Airport (DCA). ... Delta launches biometrics to board aircraft at Reagan Washington ... Delta,s biometric boarding pass experience that ... integrated into the boarding process to allow eligible Delta SkyMiles Members who ...
(Date:6/23/2017)... ITHACA, N.Y. , June 23, 2017 ... a leader in dairy research, today announced a new ... help reduce the chances that the global milk supply ... this dairy project, Cornell University has become the newest ... Food Supply Chain, a food safety initiative that includes ...
Breaking Biology News(10 mins):